

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/646,493	03/22/2002	Solomon B. Margolin	183-109(US)	9283
75	90 08/19/2005		EXAM	NER
John H Crozier			WEDDINGTON, KEVIN E	
1934 Huntington Turnpike Trumbull, CT 06611-5116			ART UNIT	PAPER NUMBER
ŕ			1614	
			DATE MAILED: 08/19/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

		7				
	Application No.	Applicant(s)				
Office Addison Commence	09/646,493	MARGOLIN, SOLOMON B.				
Office Action Summary	Examiner	Art Unit				
	Kevin E. Weddington	1614				
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REATHE MAILING DATE OF THIS COMMUNICATION  - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above, its less than thirty (30) days, a least of the second o	N. 1.136(a). In no event, however, may a reply be timediate the statutory minimum of thirty (30) days od will apply and will expire SIX (6) MONTHS from tute, cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 09	<u>) June 2005</u> .					
2a)⊠ This action is <b>FINAL</b> . 2b)□ T	his action is non-final.					
,						
Disposition of Claims						
4) ⊠ Claim(s) 1-18 is/are pending in the applicating 4a) Of the above claim(s) 1-9 is/are withdraw 5) □ Claim(s) is/are allowed.  6) ⊠ Claim(s) 10-15 is/are rejected.  7) ⊠ Claim(s) 16-18 is/are objected to.  8) □ Claim(s) are subject to restriction and	vn from consideration.					
Application Papers						
9) The specification is objected to by the Exam 10) The drawing(s) filed on is/are: a) a Applicant may not request that any objection to t Replacement drawing sheet(s) including the corr 11) The oath or declaration is objected to by the	accepted or b) objected to by the Incepted or b) objected to by the Incepted in abeyance. See rection is required if the drawing(s) is objection is	e 37 CFR 1.85(a). lected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority documed 2. Certified copies of the priority documed 3. Copies of the certified copies of the papplication from the International Burn * See the attached detailed Office action for a line of the papplication from the International Burn * See the attached detailed Office action for a line of the papplication from the International Burn * See the attached detailed Office action for a line of the papplication from the International Burn * See the attached detailed Office action for a line of the papplication from the International Burn * See the attached detailed Office action for a line of the papplication from the International Burn * See the attached detailed Office action for a line of the papplication from the International Burn * See the attached detailed Office action for a line of the papplication from the International Burn * See the attached detailed Office action for a line of the papplication from the International Burn * See the attached detailed Office action for a line of the papplication from the International Burn * See the attached detailed Office action for a line of the papplication from the International Burn * See the attached detailed Office action for a line of the papplication from the International Burn * See the attached detailed Office action for a line of the papplication from the Internation for a line of the papplication from the Internation for a line of the papplication from the Internation for a line of the papplication from the Internation for a line of the papplication from the Internation for a line of the papplication from the Internation for a line of the papplication from the Internation for a line of the papplication from the Internation for a line of the papplication from the Internation for a line of the papplication from the Internation for a line of the Internation from the Internation for a line of the Internation from the Internation from the Internation	ents have been received. ents have been received in Applicati riority documents have been receive eau (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachment(s)  1) Notice of References Cited (PTO 892)	4) 🖂 Intensions Commune	(PTO.413)				
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statement(s) (PTO-1449 or PTO/SB/Paper No(s)/Mail Date</li> </ol>	4)  Interview Summary Paper No(s)/Mail Da 08) 5)  Notice of Informal P 6)  Other:					

Claims 1-18 are presented for examination.

Claims 1-9 are withdrawn from consideration as being drawn to the non-elected invention (37 CFR 1.142(b)).

Claims 10-18 are examined.

Applicant's response filed June 9, 2005 has been received and entered.

Accordingly, the rejections made under 35 USC 112, second paragraph (in-part); 35 USC 102 and 35 USC 103 as set forth in the previous Office action dated January 6, 2005 at pages 2-9 are hereby withdrawn since the prior art, Lohaus et al. (3,883,545), teaches compounds that have a hydroxyl group in the number one (nitrogen) position of the pyridine ring. The present compounds have major non-hydroxyl substitutions on the one (nitrogen) position, which prolong the action of the substances in the body or in the surface of the skin when applied topically to the skin.

### Claim Objections

Claims 16-18 are again objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

### Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 10-15 are again rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for pirfenidone, (5-methyl-1-phenyl-2(1H)-

Application/Control Number: 09/646,493

Art Unit: 1614

pyridone), does not reasonably provide enablement for other 2-(1H) pyridones. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

In this regard, the application disclosure and claims have been compared per factors indicated in the decision <u>In re Wands</u>, 8 USPQ2d 1400 (Fed. Cir., 1988) as to undue experimentation.

The factors include:

- 1) the quantity of experimentation necessary
- 2) the amount of direction or guidance provided
- 3) the presence or absence of working examples
- 4) the nature of the invention
- 5) the state of the art
- 6) the relative skill of those in the art
- 7) the predictability of the art and
- 8) the breadth of the claims

The instant specification fails to provide guidance that would allow the skilled artisan background sufficient to practice that instant invention without resorting to undue experimentation in view of further discussion below.

As of record, for reason of record as set forth in the Office action dated January 6, 2005 at pages 2-5 as applied to claims 10-15.

Application/Control Number: 09/646,493

Art Unit: 1614

Applicant's remarks regarding all the other pyridone compounds listed in the instant specification are structurally similar and would be expected to posses the same efficaciousness in treating the listed conditions are not persuasive since the applicant have not demonstrated on the record that the other 2-(1H) pyridones are effective to treat bacteria, fungi, and/or viruses on the surface of, or within, the layers of the dermis skin, ears, fingernails, toenails, or hoofs of mammalian species. Again, the applicant only shows examples of pirfenidone to treat said conditions.

The rejection made under 35 USC 112, first paragraph is adhered to.

Claims 10-15 are not allowed.

## Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 14 is again rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 14 is again rendered indefinite and vague by the use of the phrase "etc." in line 32. As the applicant stated in the response dated June 9, 2005 that the word "etc." is used to indicate that any group having the foregoing characteristics may be substituted then the applicant may wish to amend the claim to recite such groups that are supported in the instant specification. Also in claim 14, the phrase "alkyl

Application/Control Number: 09/646,493

Art Unit: 1614

group" alone is understood in the art, therefore, the applicant may wish to delete the phrase "(CH3, C2H5, etc.)".

The rejection made under 35 USC 112, second paragraph is adhered to.

Claim 14 is not allowed.

#### Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kevin E. Weddington whose telephone number is (571)272-0587. The examiner can normally be reached on 11:00 am-7:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (571)272-0951. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 09/646,493 Page 6

Art Unit: 1614

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kevin E. Weddington Primary Examiner Art Unit 1614

K. Weddington August 16, 2005